Clinical Guides
Cirrhosis and Chronic Liver Disease
A clinically focused guide to identifying, staging and managing cirrhosis in Indian practice, with focused pathways for ascites, spontaneous bacterial peritonitis, encephalopathy, varices, hepatocellular carcinoma, nutrition, transplantation and palliative care.
MedNext Academy | 13 min read
Cirrhosis and Chronic Liver Disease
A clinically focused guide to identifying, staging and managing cirrhosis in Indian practice, with focused pathways for ascites, spontaneous bacterial peritonitis, encephalopathy, varices, hepatocellular carcinoma, nutrition, transplantation and palliative care.
Summary
Cirrhosis is advanced hepatic fibrosis with distortion of liver architecture, regenerative nodules and clinically important risks from portal hypertension and liver dysfunction. A person may remain compensated without ascites, encephalopathy or variceal bleeding, yet still have clinically significant portal hypertension and hepatocellular carcinoma (HCC) risk. Decompensation is marked by ascites, hepatic encephalopathy, portal-hypertensive gastrointestinal bleeding or related events; it changes prognosis and should trigger timely hepatology and transplant thinking rather than repeated crisis-only treatment.
The label is incomplete without a cause. Alcohol-associated liver disease, chronic hepatitis B or C, metabolic dysfunction-associated steatotic liver disease, autoimmune hepatitis, cholestatic disease, vascular disorders, Wilson disease, haemochromatosis and drug or supplement injury require different investigations and disease-modifying treatment. More than one cause may coexist. In India, viral-hepatitis services, alcohol stigma, diabetes, delayed presentation, travel and transplant access shape practical care.
Management has four simultaneous tracks: treat the cause; stage liver function and portal hypertension; prevent, detect and treat complications; and address nutrition, frailty, symptoms and goals. New ascites needs diagnostic paracentesis when feasible, suspected spontaneous bacterial peritonitis (SBP) needs urgent fluid analysis and treatment, and altered mentation demands a search for precipitants and alternatives. Variceal and HCC surveillance must be actively arranged. Medicines require renal, haemodynamic and encephalopathy awareness. Palliative care can begin alongside transplant assessment. This quarantined guide supports education, not unsupervised diuretic, antibiotic, beta-blocker or lactulose adjustment.
How Common Is It?
Cirrhosis burden is difficult to express as one current Indian percentage. Many people remain undiagnosed until thrombocytopenia, imaging, ascites, bleeding, jaundice or encephalopathy reveals advanced disease. Administrative data capture hospitalised decompensation more readily than compensated disease; elastography-based surveys use different thresholds; and the mix of viral, alcohol-associated and metabolic disease varies by region, age, sex and access. A precise national prevalence should therefore not be inferred from a single centre or an older screening study.
Chronic hepatitis B and C can progress through fibrosis to cirrhosis and HCC. India's National Viral Hepatitis Control Programme was established to support prevention, testing and treatment, but availability and linkage to specialist care remain locally variable. Alcohol-associated liver disease and metabolic dysfunction associated with diabetes, central adiposity and dyslipidaemia are also important. A person may have hepatitis plus alcohol exposure or metabolic risk; mutually exclusive labels underestimate progression. Autoimmune, cholestatic, genetic and vascular causes are individually less common but clinically consequential because specific treatment may change outcome.
Complication burden matters more than a headline prevalence. Ascites can impair mobility and breathing, encephalopathy can remove driving and work safety, and variceal bleeding can be fatal without rapid care. Repeated procedures, transport, caregiver time, nutrition costs and loss of income amplify illness. Service planning should count people needing surveillance, paracentesis, endoscopy, antiviral treatment, transplantation and palliative support, not merely deaths coded as cirrhosis. At the bedside, never use population frequency to bypass a complete aetiological assessment.
Risk Factors
Ask about alcohol without moral language: type, quantity, pour size, frequency, binges, dependence features, withdrawal, previous attempts to reduce and household impact. Convert cautiously to standard alcohol units because local beverages and unmeasured spirits vary. Abrupt unsupervised cessation can be dangerous in a dependent person, so withdrawal risk needs medical planning. Record hepatitis B vaccination, transfusion or surgery history, dialysis, injecting drug use, tattoos, needle or healthcare exposures, maternal or household HBV, sexual risk and previous hepatitis testing or treatment.
Assess metabolic risk through diabetes, waist or body mass, dyslipidaemia, hypertension, sleep apnoea and sedentary behaviour. Lean appearance does not exclude metabolic steatotic liver disease in South Asian populations. Review autoimmune disease, inflammatory bowel disease, family liver disease, early emphysema, neuropsychiatric symptoms, thrombosis, heart failure and congenital conditions. Medicines, bodybuilding agents, traditional remedies, herbals and supplements need exact names, dates and photographs of packaging; 'natural' is not a safety category.
Progression and decompensation are promoted by continued causative injury, bacterial infection, renal dysfunction, malnutrition, sarcopenia and portal hypertension. Prior ascites, SBP, encephalopathy or bleeding predicts recurrence. NSAIDs, sedatives, dehydration and inappropriate diuretic escalation can precipitate kidney injury or encephalopathy. Constipation, gastrointestinal bleeding, infection, excess diuresis and electrolyte disturbance are common encephalopathy triggers. HCC risk persists in cirrhosis even after viral suppression or cure, although magnitude changes. Family, financial and geographic constraints influence whether surveillance and transplant evaluation occur on time and should be documented as clinical risk, not patient noncompliance.
Diagnosis
History
Define the possible cause, duration and first evidence of liver disease. Ask about jaundice, pruritus, abdominal distension, oedema, reduced urine, early satiety, muscle loss, bruising, haematemesis, melaena, sleep reversal, confusion, falls and altered work or driving. Seek previous ascites taps, SBP, encephalopathy, endoscopy, banding, transfusion, HCC imaging, antiviral therapy and admissions. Record alcohol, metabolic, viral, drug, supplement, autoimmune, family and thrombotic histories. Obtain collateral history for cognition and medication use because encephalopathy can reduce insight.
Examination
Assess haemodynamic stability, temperature, oxygenation, hydration, cognition and asterixis. Look for jaundice, pallor, bruising, muscle wasting, parotid enlargement, spider telangiectasia and palmar erythema without treating any sign as diagnostic alone. Examine abdomen for hepatomegaly or a small liver, splenomegaly, ascites, tenderness, hernia and collateral veins. Record oedema, jugular venous pressure and cardiac findings. Fever, hypotension, diffuse tenderness or worsening encephalopathy in ascites raises urgent concern for infection. Nutrition and frailty assessment includes weight trajectory, mid-arm or functional measures and ability to shop, cook and mobilise.
Investigations
Initial tests commonly include blood count, bilirubin, aminotransferases, alkaline phosphatase, albumin, creatinine, sodium, glucose and prothrombin time/INR, with aetiology-directed viral serology, autoimmune markers, iron studies and selected ceruloplasmin or alpha-1 antitrypsin testing. Ultrasound assesses morphology, portal features, spleen, ascites and focal lesions; elastography supports fibrosis assessment but can be confounded by inflammation or congestion. Calculate Child-Pugh for familiar clinical staging and MELD-based scores for short-term risk and transplant systems, recognising that neither replaces judgement. Diagnostic paracentesis should provide cell count with differential, culture inoculated appropriately and albumin/protein where indicated; an ascitic neutrophil count of at least 250 cells per microlitre supports SBP treatment.
Differential Diagnosis
Advanced fibrosis is not the only cause of a nodular liver, ascites, jaundice or confusion. Non-cirrhotic portal hypertension can arise from portal-vein thrombosis, schistosomiasis, porto-sinusoidal vascular disorder or other vascular disease, sometimes with preserved synthetic function. Budd-Chiari syndrome, right-heart failure and constrictive pericarditis can cause congestive hepatopathy and high-gradient ascites. Malignant portal infiltration or peritoneal carcinomatosis may mimic decompensation. Ultrasound with Doppler, ascitic albumin gradient and protein, cardiac assessment and cross-sectional imaging are selected according to the pattern.
Acute hepatitis, biliary obstruction, sepsis-related cholestasis and drug-induced liver injury may present with jaundice and coagulopathy without established cirrhosis. Acute-on-chronic liver failure is a distinct severe syndrome with organ failures and high short-term mortality; do not reduce it to an elevated bilirubin. Nephrotic syndrome, pancreatic disease, tuberculosis and malignancy are alternative causes of ascites. In India, tuberculous peritonitis deserves consideration when fever, weight loss, pain, lymphocytes or low-gradient ascites are present, but empirical treatment without adequate sampling can hide malignancy or resistant disease.
Altered mentation is not automatically hepatic encephalopathy. Hypoglycaemia, sepsis, intracranial bleeding, stroke, alcohol withdrawal, sedative toxicity, uraemia, sodium disturbance and non-convulsive seizures require exclusion. Ammonia concentration does not grade encephalopathy reliably and a normal value should prompt diagnostic reconsideration. A focal liver lesion may be HCC, cholangiocarcinoma, metastasis, abscess or benign lesion; surveillance ultrasound is not definitive diagnosis. Finally, thrombocytopenia may reflect marrow, immune or drug causes, and a mildly abnormal INR in cirrhosis does not by itself describe total bleeding risk.
Management
Treat the cause whenever possible: sustained alcohol abstinence with dependence care, HBV suppression, curative HCV therapy, metabolic risk treatment, immunosuppression for verified autoimmune hepatitis, or disease-specific management for cholestatic, vascular or genetic disorders. Vaccinate susceptible people against hepatitis A and B as appropriate. Review all prescriptions and non-prescribed products. Nutrition should protect muscle: avoid routine protein restriction, distribute adequate protein and energy through the day, minimize long fasting and consider a late-evening snack. Exercise and resistance work are individualized to frailty, falls and variceal status.
Ascites management combines moderate dietary sodium restriction, daily trends and carefully monitored diuretics. Tense or refractory ascites may require large-volume paracentesis with albumin replacement according to protocol, evaluation for transjugular intrahepatic portosystemic shunt (TIPS) and transplant referral. New or worsening ascites, admission or compatible symptoms should prompt diagnostic paracentesis; suspected SBP needs urgent empiric antibiotic therapy after cultures when this does not delay care. Secondary antibiotic prophylaxis and selected primary prophylaxis require local resistance, renal and adverse-effect review.
For encephalopathy, identify and correct infection, bleeding, constipation, electrolyte disturbance, dehydration, sedatives or nonadherence. Lactulose is titrated to regular soft stools without diarrhoeal dehydration; rifaximin is commonly added for recurrent episodes. Portal-hypertension care includes non-selective beta-blocker or endoscopic strategies in appropriate patients, and acute variceal bleeding requires resuscitation, vasoactive therapy, antibiotic prophylaxis and urgent endoscopic control. Arrange HCC surveillance, generally at six-month intervals. After decompensation or HCC, refer early for transplant evaluation. Integrate palliative care for symptoms, caregiver strain and decisions regardless of transplant candidacy.
Prescribing Information
Cirrhosis changes pharmacokinetics, protein binding, renal vulnerability and susceptibility to encephalopathy. Reconcile every prescription, over-the-counter analgesic, sedative, herbal mixture and supplement. Avoid NSAIDs in decompensated cirrhosis because renal injury, sodium retention and bleeding can follow. Paracetamol may be used within a clinician-defined reduced ceiling in many patients but must account for alcohol use, low body weight, combination products and nutrition; this guide does not set a universal dose. Opioids, benzodiazepines, gabapentinoids and sedating antihistamines require a compelling indication, low starting exposure and monitoring rather than automatic prohibition or casual continuation.
Diuretics are adjusted against weight, blood pressure, sodium, potassium and creatinine. Spironolactone often anchors ascites therapy and furosemide may balance potassium and improve diuresis, but fixed ratios are teaching conventions, not a substitute for individual monitoring. Stop or reduce therapy when severe hyponatraemia, acute kidney injury, symptomatic hypotension, troublesome potassium disturbance or encephalopathy develops and seek specialist advice. Large-volume paracentesis requires an albumin protocol. Do not use routine albumin as an undefined tonic.
Non-selective beta-blockers such as carvedilol or propranolol can prevent decompensation or bleeding in selected portal-hypertension contexts, yet hypotension, renal dysfunction and advanced refractory ascites demand review. Lactulose is titrated to effect; excessive diarrhoea can precipitate dehydration and recurrence. Rifaximin is generally adjunctive after recurrent encephalopathy. SBP treatment and prophylaxis should follow microbiology and local antimicrobial stewardship because resistance differs. Proton-pump inhibitors need a clear indication. Warfarin or direct anticoagulant decisions require specialist risk assessment; an elevated INR from cirrhosis neither provides anticoagulation nor automatically forbids it.
When to Refer
Every confirmed cirrhosis diagnosis merits specialist hepatology or gastroenterology input to establish cause, stage portal hypertension, arrange variceal and HCC surveillance and plan complication prevention. Expedite referral for first ascites, encephalopathy, variceal bleeding, jaundice, renal deterioration, severe hyponatraemia, sarcopenia, recurrent infection, suspected HCC, refractory symptoms or uncertain diagnosis. Viral hepatitis should link to treatment pathways rather than remain a laboratory label. Autoimmune, cholestatic, vascular, genetic and drug-induced disease may need centre-specific tests and therapy.
Discuss transplant assessment after the first decompensating event, significant HCC or a concerning MELD trajectory; referral should precede irreversible frailty or recurrent organ failure. Listing depends on disease severity, reversibility, comorbidity, infection, malignancy criteria, psychosocial assessment, alcohol-use management, adherence capacity and local programme rules. Palliative care referral is also appropriate for refractory ascites, pruritus, pain, breathlessness, recurrent encephalopathy, caregiver burden or uncertainty. It can occur during antiviral therapy, TIPS assessment or transplant listing and does not mean abandonment.
Emergency transfer is required for haematemesis or melaena with instability, new severe confusion or reduced consciousness, fever or abdominal pain with ascites, oliguria, shock, rapidly deepening jaundice, severe electrolyte disturbance or suspected sepsis. Suspected SBP should not wait for routine clinic. Acute variceal bleeding needs a facility able to resuscitate, give vasoactive and antimicrobial therapy and provide urgent endoscopy, with escalation pathways for uncontrolled bleeding. Communicate the last endoscopy, medications, allergies, baseline cognition, transplant status and prior resistant organisms during transfer.
Red Flags
Gastrointestinal bleeding in cirrhosis is an emergency even when an initial blood pressure is normal. Haematemesis, melaena, syncope, tachycardia, falling haemoglobin or rising urea may precede shock. Protect the airway when consciousness is impaired, resuscitate thoughtfully and activate endoscopic and critical-care pathways. Over-transfusion can worsen portal pressure, while under-resuscitation worsens organ perfusion; use current local protocols and senior supervision rather than a rigid target detached from the patient's condition.
SBP may present with fever, abdominal pain or tenderness, hypotension, kidney injury, ileus or encephalopathy, but symptoms can be subtle. Diagnostic paracentesis is urgent in new or worsening ascites and suitable admissions. An ascitic neutrophil count at or above 250 cells per microlitre warrants treatment in the appropriate setting even if culture is negative. Secondary peritonitis must be considered with a surgically treatable source, unusual fluid chemistry, polymicrobial culture or poor response.
New confusion, sleep reversal or asterixis requires glucose, infection, bleeding, medication, renal and electrolyte assessment; do not delay emergency care to obtain an ammonia value. Rapid creatinine rise, oliguria, severe hyponatraemia or hypotension may signal hypovolaemia, sepsis, drug harm or hepatorenal physiology. A new focal lesion, weight loss, bone pain or unexplained decompensation raises HCC concern. Painful tense hernia, respiratory compromise from ascites and acute portal-vein thrombosis also need urgent review. Caregiver inability to maintain medicines or safety, repeated falls and loss of decision-making capacity are clinical red flags requiring support and documented advance-care discussion.
Indian Clinical Context
A useful Indian pathway begins with cause and access. Offer validated HBV and HCV testing and link positive results to National Viral Hepatitis Control Programme or other verified treatment services; do not tell a person that cirrhosis makes antiviral therapy futile. Ask sensitively about locally produced alcohol and dependence, recognising both stigma and the medical danger of withdrawal. Diabetes and metabolic risk may coexist with alcohol or viral hepatitis. Traditional medicines and supplements should be discussed without ridicule so that potential hepatotoxic products are actually disclosed.
Diagnostic and therapeutic capacity varies. Elastography, endoscopy, interventional radiology, albumin, rifaximin and transplant evaluation may require travel or substantial out-of-pocket cost. Build a plan around the actual district or tertiary facility: who can perform urgent paracentesis, where variceal bleeding goes, how surveillance imaging is booked, and what happens if a patient cannot return in six months. Ascitic fluid cell counting and culture quality matter; repeated empirical antibiotics without taps can drive resistance and miss TB or malignancy.
Counselling should fit diet and household reality. Sodium reduction means identifying added salt, pickles, papad, packaged snacks and restaurant foods without prescribing starvation. Protein restriction is harmful for most patients; use affordable pulses, dairy, eggs or other acceptable sources, adapted for renal and cultural needs. Families often supervise lactulose, cognition and transport and need clear written triggers for care. international and AASLD recommendations are evidence anchors, not an Indian formulary or transplant entitlement. Document affordability, generic options, local resistance patterns, language, caregiver availability and the referral centre by name.
NMC Competency Mapping
The 2024 NMC curriculum maps liver disease to General Medicine topic GM5. GM5.2 covers aetiology and pathophysiology of liver disease; GM5.3 and GM5.4 address viral hepatitis and alcohol-associated liver disease. GM5.5 explicitly requires understanding cirrhosis and portal-hypertension complications, including ascites, SBP, hepatorenal syndrome, encephalopathy, acute gastrointestinal bleeding and HCC. Pathology competencies PA24.4, PA24.5 and PA24.7 reinforce alcohol-associated cirrhosis, portal hypertension and HCC.
Clinical method is mapped through GM5.8 for an aetiological history, GM5.9 for a systematic examination including nutrition, mental state, jaundice, ascites and portal-systemic signs, and GM5.10 for differential diagnosis. GM5.11 to GM5.13 cover blood tests, hepatitis serology, ascitic fluid and imaging. GM5.14 is a supervised skill outcome for assisting with and interpreting ascitic fluid analysis. Reading this guide does not certify paracentesis, which requires consent, asepsis, anatomy, complication management and direct observation.
GM5.15 covers management of hepatitis, cirrhosis, portal hypertension, ascites, SBP, acute bleeding, encephalopathy and HCC. GM5.16 addresses hepatitis vaccination counselling and GM5.17 hepatic-transplant indications. Learners should connect these outcomes rather than memorise isolated lists: identify decompensation, stabilise emergencies, find the precipitant, interpret renal and synthetic function, prevent recurrence and communicate prognosis. NMC mapping is educational; drug selection, endoscopy, paracentesis, TIPS and transplant decisions remain supervised clinical responsibilities governed by current local policy.
Key Exam Pearls for NEET PG
Compensated cirrhosis has not yet produced ascites, encephalopathy or variceal bleeding; any of these marks decompensation and a major prognostic transition. Portal hypertension causes splenomegaly, thrombocytopenia, collateral formation, varices and ascites, but platelet count alone does not diagnose cirrhosis. Child-Pugh uses bilirubin, albumin, INR, ascites and encephalopathy. MELD-based scores use objective laboratory variables to estimate short-term risk and inform transplant systems. Neither score replaces cause, trajectory or acute organ failure assessment.
For new ascites, perform diagnostic paracentesis and calculate the serum-ascites albumin gradient when relevant. A gradient of at least 1.1 g/dL supports portal-hypertension physiology. Ascitic neutrophils at least 250 cells per microlitre meet the standard treatment threshold for SBP in context. Treat first-line ascites with sodium moderation and monitored diuretics; tense ascites favours therapeutic paracentesis with protocol-based albumin. Avoid NSAIDs. Refractory ascites prompts TIPS and transplant assessment, not endlessly escalating diuretics despite kidney injury.
Hepatic encephalopathy is clinical: find bleeding, infection, constipation, dehydration, renal failure, electrolyte disturbance and sedatives. Lactulose targets regular soft stools; excess diarrhoea can worsen it. Add rifaximin for recurrent episodes. Acute variceal bleeding requires resuscitation, vasoactive drug, antibiotic prophylaxis and urgent endoscopic therapy. Primary prevention uses an appropriate non-selective beta-blocker or endoscopic strategy based on portal-hypertension assessment. Cirrhosis requires HCC surveillance about every six months unless goals or candidacy make surveillance non-beneficial. First decompensation should bring transplant referral and early palliative support into the same plan.
Frequently Asked Questions
What is the clinical difference between compensated and decompensated cirrhosis?
Compensated cirrhosis has not produced the defining clinical events of ascites, hepatic encephalopathy or portal-hypertensive bleeding. The first such event marks decompensation and substantially changes risk, follow-up and treatment planning. It should prompt hepatology review, complication prevention and timely transplant consideration rather than being managed as an isolated admission.
Why is diagnostic paracentesis important when a patient with cirrhosis develops ascites?
Fluid analysis identifies infection and helps distinguish portal-hypertension ascites from alternative causes. SBP may be subtle, and an ascitic neutrophil count of at least 250 cells per microlitre supports urgent treatment in the correct setting. Albumin and protein, culture and other tests are selected according to the presentation and local laboratory capability.
Should protein be restricted when hepatic encephalopathy develops in cirrhosis?
Routine protein restriction is not recommended and can worsen sarcopenia, frailty and recovery. Management should instead identify the precipitant, use lactulose correctly and add other therapy when indicated while maintaining adequate, distributed protein and energy intake. Short individualized adjustments may occasionally be made by the treating team, but prolonged low-protein diets are harmful.
Can palliative care be offered while a patient is being assessed for liver transplantation?
Yes. Palliative care addresses pain, pruritus, breathlessness, sleep, anxiety, caregiver strain, serious-illness communication and advance-care planning. It can be delivered alongside antiviral therapy, paracentesis, TIPS or transplant listing. It does not make a patient ineligible for active treatment and should not be reserved for the last days of life.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic